Xiao Jing, Lan Yu, Yan Lin, Zhang Ming Bo, Zhang Yan, Xie Fang, Song Qing, Luo Yu Kun, Tang Jie
School of Medicine,Nankai University,Tianjin 300071,China.
Department of Ultrasound,the First Medical Center of Chinese PLA General Hospital,Beijing 100853,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Dec 30;42(6):771-775. doi: 10.3881/j.issn.1000-503X.12731.
Objective To investigate the short-term outcome of T1bN0M0 papillary thyroid cancer after ultrasonography-guided radiofrequency ablation(RFA). Methods Eighty-nine patients with T1bN0M0 papillary thyroid cancer who were treated with ultrasonography-guided RFA in our center from April 2014 to January 2019 were retrospectively analyzed.Trans-isthmus approach and moving shot technique were used during the RFA procedure.Ultrasonography and contrast-enhanced ultrasonography were performed before ablation,and immediately,1,3,6 and 12 months after ablation and then every 6 months thereafter. Results RFA was performed in 89 cases of papillary thyroid cancer,and no major complications were observed during the RFA.The mean follow-up was(18.8±7.3)months.The ablation zones decreased gradually during follow-up,and 38 ablation zones(42.7%)completely disappeared.The volume reduction rate was(99.2±2.3)% 30 months after ablation.During follow-up,2 patients(2.2%)developed tumor recurrence and 1 patient(1.1%)developed cervical lymph node metastasis. Conclusion Ultrasonography-guided RFA may be a safe and effective method for patients with T1bN0M0 papillary thyroid cancer.
目的 探讨超声引导下射频消融(RFA)治疗T1bN0M0 期甲状腺乳头状癌的短期疗效。方法 回顾性分析2014年4月至2019年1月在本中心接受超声引导下RFA治疗的89例T1bN0M0期甲状腺乳头状癌患者。RFA过程中采用经峡部入路和移动射击技术。消融前、消融即刻、消融后1、3、6和12个月以及此后每6个月进行超声及超声造影检查。结果 89例甲状腺乳头状癌患者接受了RFA治疗,RFA过程中未观察到严重并发症。平均随访时间为(18.8±7.3)个月。随访期间消融区逐渐缩小,38个消融区(42.7%)完全消失。消融后30个月体积缩小率为(99.2±2.3)%。随访期间,2例患者(2.2%)出现肿瘤复发,1例患者(1.1%)出现颈部淋巴结转移。结论 超声引导下RFA可能是治疗T1bN0M0期甲状腺乳头状癌患者的一种安全有效的方法。